Literature DB >> 15276398

Osteomyelitis.

Daniel P Lew1, Francis A Waldvogel.   

Abstract

Bone and joint infections are painful for patients and frustrating for both them and their doctors. The high success rates of antimicrobial therapy in most infectious diseases have not yet been achieved in bone and joint infections owing to the physiological and anatomical characteristics of bone. The key to successful management is early diagnosis, including bone sampling for microbiological and pathological examination to allow targeted and long-lasting antimicrobial therapy. The various types of osteomyelitis require differing medical and surgical therapeutic strategies. These types include, in order of decreasing frequency: osteomyelitis secondary to a contiguous focus of infection (after trauma, surgery, or insertion of a joint prosthesis); that secondary to vascular insufficiency (in diabetic foot infections); or that of haematogenous origin. Chronic osteomyelitis is associated with avascular necrosis of bone and formation of sequestrum (dead bone), and surgical debridement is necessary for cure in addition to antibiotic therapy. By contrast, acute osteomyelitis can respond to antibiotics alone. Generally, a multidisciplinary approach is required for success, involving expertise in orthopaedic surgery, infectious diseases, and plastic surgery, as well as vascular surgery, particularly for complex cases with soft-tissue loss.

Entities:  

Mesh:

Year:  2004        PMID: 15276398     DOI: 10.1016/S0140-6736(04)16727-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  460 in total

Review 1.  Treatment of spondylodiscitis.

Authors:  Kourosh Zarghooni; Marc Röllinghoff; Rolf Sobottke; Peer Eysel
Journal:  Int Orthop       Date:  2011-12-06       Impact factor: 3.075

Review 2.  Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity.

Authors:  James E Cassat; Eric P Skaar
Journal:  Semin Immunopathol       Date:  2011-11-03       Impact factor: 9.623

Review 3.  Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review.

Authors:  Susmita Bose; Solaiman Tarafder
Journal:  Acta Biomater       Date:  2011-11-20       Impact factor: 8.947

Review 4.  [Bone infections].

Authors:  A H Tiemann; R Braunschweig; G O Hofmann
Journal:  Unfallchirurg       Date:  2012-06       Impact factor: 1.000

5.  Adjunctive therapies in the treatment of osteomyelitis.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

6.  Predicting the pathogen of diabetic toe osteomyelitis by two consecutive ulcer cultures with bone contact.

Authors:  L Bernard; M Assal; C Garzoni; I Uçkay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-10       Impact factor: 3.267

7.  Endocarditis associated with vertebral osteomyelitis and septic arthritis of the axial skeleton.

Authors:  Oscar Murillo; Imma Grau; Joan Gomez-Junyent; Celina Cabrera; Alba Ribera; Fe Tubau; Carmen Peña; Javier Ariza; Roman Pallares
Journal:  Infection       Date:  2018-02-02       Impact factor: 3.553

8.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection.

Authors:  Cortney E Heim; Debbie Vidlak; Tyler D Scherr; Curtis W Hartman; Kevin L Garvin; Tammy Kielian
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

10.  Musculoskeletal infection imaging: past, present, and future.

Authors:  Santiago Restrepo; Daniel Vargas; Roy Riascos; Hugo Cuellar
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.